Eliem Therapeutics is a clinical-stage biotechnology company. Founded by David-Alexandre Gros in 2018, Eliem Therapeutics is backed by investors that include RA Capital Management, Intermediate Capital Group, and Access Biotechnology and is headquartered in Boston.